ResearchHub Foundation(@ResearchHubF):WSJ followed refractory cancer patients flying to Shanghai for CAR-T. China: $150K–$230K US: $550K–$850K One hospital, SinoUnited, has treated three dozen patients from 12 countries since 2023. Its founder says most are now cancer-free. It’s just a single center's own count, with no published follow-up. Those outcomes sit in no registry, and nobody has funded the study that would check them.

2026.09.12 03:18

WSJ followed refractory cancer patients flying to Shanghai for CAR-T. China: $150K–$230K US: $550K–$850K One hospital, SinoUnited, has treated three dozen patients from 12 countries since 2023. Its founder says most are now cancer-free. It’s just a single center's own count, with no published follow-up. Those outcomes sit in no registry, and nobody has funded the study that would check them.

Eric Topol@EricTopol

2026.09.10 14:08

Patients with refractory cancer seeking treatment with engineered T cells (CAR T) are going to China where the cost is considerably less China $150-300K US $550-800K